24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
For packaging engineers, each material decision begins with barrier integrity, migration profiles, and stability projections. As sustainability expectations tighten across the pharmaceutical sector, biodegradable packaging is no longer just a concept—it’s entering procurement cycles and stability trials. Meanwhile, sustainability targets keep tightening. That is why biodegradable pharmaceutical packaging is attracting serious attention on plant floors and in procurement reviews. One data point sets the context. Packaging accounts for roughly 37–45% of plastic waste across major economies, putting the spotlight squarely on the materials that protect medicines every day.
Pharmaceutical supply chains rely on plastics for sterility, barrier performance and transport safety. The result is a significant single-use material flow, much of which is difficult to reclaim once it enters clinical or production environments. When rigorously selected and validated, biodegradable options reduce reliance on landfills and support defined, compliant end-of-life pathways across healthcare facilities and production lines. The direction of travel is clear. Policymakers are restricting single-use formats, and recycling targets for packaging are increasing across major regions.
Progress in polymers is widening the toolkit. Plant-based materials, such as polylactic acid and polyhydroxyalkanoates, are improving in mechanical strength and barrier performance. Cellulose derivatives and bio-composites confer moisture- and oxygen-resistance that earlier generations lacked. Engineers now use multilayer structures or apply targeted coatings to meet the barrier and stability needs of specific dosage forms and packaging configurations. Reviews in the technical literature report that, when properly designed, these materials can achieve practical gas and vapour transmission rates, making them candidates for secondary packaging and, in some scenarios, certain primary applications following rigorous validation.
Any packaging change must comply with Good Manufacturing Practice (GMP) and International Council for Harmonisation (ICH) requirements. That means conducting extractables and leachables studies, verifying barriers under stability conditions, and providing clear documentation for packaging validation. Teams typically stress-test new materials at 40 °C and 75% relative humidity as part of ICH stability work, and then confirm tolerances for Water Vapor Transmission Rate (WVTR) and Oxygen Transmission Rate (OTR) against product requirements. Successful pilots pair material selection with a defined risk assessment and a change-control plan that brings Quality Assurance, Regulatory Affairs and Production into the same conversation.
Sustainability is not only a reputational goal. Waste-handling costs fall when fewer non-recoverable plastics move through the system. Lightweight structures can cut transport mass, and local availability of bio-feedstocks can shorten lead times. Procurement teams increasingly evaluate suppliers on Environmental, Social & Governance (ESG) criteria, meaning better end-of-life outcomes and transparent reporting directly improve supplier scores. Market analysts are also tracking strong growth in sustainable pharma packaging categories, which signals increased availability and competitive pricing over the next cycle.
Biodegradable inputs come with practical limits. Feedstock quality can vary by season. Barrier performance may shift under humidity stress. Sterilisation compatibility needs evidence, not theory. The safest path is phased adoption. Start with secondary or tertiary formats, then evaluate contact-sensitive uses once data and process controls are in place. Supplier audits should verify the identity of raw materials, additive profiles, and consistency controls. Contracts can include clear change-notification timing, shelf-life evidence, and corrective-action procedures to prevent surprises from reaching the line.
A focused checklist keeps on-stand discussions productive.
Event programmes bring together materials scientists, packaging engineers, and validation leads in the same halls. If you plan to visit the pharma trade show, map time across adjacent pharmaceutical exhibition sectors so lab analytics, automation, and packaging teams can cross-check assumptions. Short sessions often cover barrier testing, sterilisation studies, and documentation frameworks that save weeks. To stay up to date on real-time agenda shifts and floor highlights, teams monitor Pharmtech's latest news and adjust their routes to catch the most relevant demonstrations. When you want to time a format change or review a validation pack side by side, a large pharma manufacturing expo makes this practical.
If you develop sustainable materials, barrier technologies, or validation services, submit a Pharmtech expo exhibitor enquiry to present evidence to decision-makers. We will assist you in designing concise demonstrations, developing a documentation package that addresses common audit questions, and scheduling meetings with technical and procurement leads. You’ll receive a stand plan, proof-point checklist, and meeting schedule designed to move technical conversations toward defined procurement or pilot decisions.
